Table of Contents Author Guidelines Submit a Manuscript
Journal of Osteoporosis
Volume 2014, Article ID 682763, 7 pages
http://dx.doi.org/10.1155/2014/682763
Research Article

Changes in Dickkopf-1 (DKK1) and Sclerostin following a Loading Dose of Vitamin D2 (300,000 IU)

1Department of Clinical Chemistry, St Thomas’ Hospital, North Wing, Lambeth Palace Road, London SE1 7EH, UK
2Wellchild Laboratory, The Evelina Children’s Hospital, London SE1 7EH, UK
3Metabolic Bone Clinic, Department of Rheumatology, Guy’s Hospital, London SE1 9RT, UK

Received 4 July 2014; Accepted 14 November 2014; Published 24 November 2014

Academic Editor: Teruki Sone

Copyright © 2014 A. Sankaralingam et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. H. Anderson, B. K. May, and H. A. Morris, “Vitamin D metabolism: new concepts and clinical implications,” The Clinical Biochemist Reviews, vol. 24, no. 1, pp. 13–26, 2003. View at Google Scholar
  2. T. Shimada, H. Hasegawa, Y. Yamazaki et al., “FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis,” Journal of Bone and Mineral Research, vol. 19, no. 3, pp. 429–435, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. P. W. Jurutka, L. Bartik, G. K. Whitfield et al., “Vitamin D receptor: key roles in bone mineral pathophysiology, molecular mechanism of action, and novel nutritional ligands,” Journal of Bone and Mineral Research, vol. 22, no. 2, pp. V2–V10, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Takeda, T. Yoshizawa, Y. Nagai et al., “Stimulation of osteoclast formation by 1,25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells: Studies using VDR knockout mice,” Endocrinology, vol. 140, no. 2, pp. 1005–1008, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. H. A. Bischoff-Ferrari, T. Dietrich, E. J. Orav, and B. Dawson-Hughes, “Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults,” The American Journal of Medicine, vol. 116, no. 9, pp. 634–639, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. H. A. Bischoff-Ferrari, W. C. Willett, J. B. Wong et al., “Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials,” Archives of Internal Medicine, vol. 169, no. 6, pp. 551–561, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. K. M. Sanders, A. L. Stuart, E. J. Williamson et al., “Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial,” Journal of the American Medical Association, vol. 303, no. 18, pp. 1815–1822, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Smith, F. Anderson, H. Raphael, P. Maslin, S. Crozier, and C. Cooper, “Effect of annual intramuscular vitamin D on fracture risk in elderly men and women—a population-based, randomized, double-blind, placebo-controlled trial,” Rheumatology, vol. 46, no. 12, pp. 1852–1857, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Rossini, D. Gatti, O. Viapiana et al., “Short-term effects on bone turnover markers of a single high dose of oral vitamin D3,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 4, pp. E622–E626, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Rossini, S. Adami, O. Viapiana et al., “Dose-dependent short-term effects of single high doses of oral vitamin D3 on bone turnover markers,” Calcified Tissue International, vol. 91, no. 6, pp. 365–369, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Turner, N. Dalton, R. Inaoui, I. Fogelman, W. D. Fraser, and G. Hampson, “Effect of a 300 000-IU loading dose of ergocalciferol (vitamin D2) on circulating 1,25(OH)2-vitamin D and fibroblast growth factor-23 (FGF-23) in vitamin D insufficiency,” Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 2, pp. 550–556, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. G. J. Atkins, P. S. Rowe, H. P. Lim et al., “Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism,” Journal of Bone and Mineral Research, vol. 26, no. 7, pp. 1425–1436, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Morvan, K. Boulukos, P. Clément-Lacroix et al., “Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass,” Journal of Bone and Mineral Research, vol. 21, no. 6, pp. 934–945, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Bellido, A. A. Ali, I. Gubrij et al., “Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis,” Endocrinology, vol. 146, no. 11, pp. 4577–4583, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. F. S. Mirza, I. D. Padhi, L. G. Raisz, and J. A. Lorenzo, “Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women,” The Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 4, pp. 1991–1997, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. O. Viapiana, E. Fracassi, S. Troplini et al., “Sclerostin and DKK1 in primary hyperparathyroidism,” Calcified Tissue International, vol. 92, no. 4, pp. 324–329, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. B. Dawson-Hughes, S. S. Harris, L. Ceglia, and N. J. Palermo, “Effect of supplemental vitamin D and calcium on serum sclerostin levels,” European Journal of Endocrinology, vol. 170, no. 4, pp. 645–650, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. O. Aguilera, C. Peña, J. M. García et al., “The Wnt antagonist DICKKOPF-1 gene is induced by 1α,25-dihydroxyvitamin D3 associated to the differentiation of human colon cancer cells,” Carcinogenesis, vol. 28, no. 9, pp. 1877–1884, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Ohnaka, M. Tanabe, H. Kawate, H. Nawata, and R. Takayanagi, “Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts,” Biochemical and Biophysical Research Communications, vol. 329, no. 1, pp. 177–181, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Karim, C. Turner, N. Dalton et al., “The relationship between pro-resorptive inflammatory cytokines and the effect of high dose vitamin D supplementation on their circulating concentrations,” International Immunopharmacology, vol. 17, no. 3, pp. 693–697, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Romagnoli, M. L. Mascia, C. Cipriani et al., “Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 8, pp. 3015–3020, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Qian, J. Xie, S. Hong et al., “Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma,” Blood, vol. 110, no. 5, pp. 1587–1594, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Tian, F. Zhan, R. Walker et al., “The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma,” The New England Journal of Medicine, vol. 349, no. 26, pp. 2483–2494, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. F. D. S. Rabelo, L. M. H. da Mota, R. A. C. Lima et al., “The Wnt signaling pathway and rheumatoid arthritis,” Autoimmunity Reviews, vol. 9, no. 4, pp. 207–210, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Hampson, S. Edwards, S. Conroy, G. M. Blake, I. Fogelman, and M. L. Frost, “The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women,” Bone, vol. 56, no. 1, pp. 42–47, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Gatti, O. Viapiana, L. Idolazzi, E. Fracassi, M. Rossini, and S. Adami, “The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 5, pp. 1555–1559, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. D. Gatti, O. Viapiana, E. Fracassi et al., “Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab,” Journal of Bone and Mineral Research, vol. 27, no. 11, pp. 2259–2263, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Gatti, O. Viapiana, S. Adami, L. Idolazzi, E. Fracassi, and M. Rossini, “Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin,” Bone, vol. 50, no. 3, pp. 739–742, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Gifre, S. Ruiz-Gaspa, A. Monegal et al., “Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover,” Bone, vol. 57, no. 1, pp. 272–276, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Catalano, N. Morabito, G. Basile, S. Brancatelli, D. Cucinotta, and A. Lasco, “Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis,” Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 5, pp. 1911–1915, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. U. I. Mödder, K. A. Hoey, S. Amin et al., “Relation of age, gender, and bone mass to circulating sclerostin levels in women and men,” Journal of Bone and Mineral Research, vol. 26, no. 2, pp. 373–379, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. Z. C. Ryan, H. Ketha, M. S. McNulty et al., “Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 15, pp. 6199–6204, 2013. View at Publisher · View at Google Scholar · View at Scopus